Energenesis Biomedical to Present Clinical Application of ENERGI-F703DFU for Diabetic Foot Ulcers at EWMA 2026

TAIPEI, April 29, 2026 /PRNewswire/ -- Energenesis Biomedical Co., Ltd. (TWSE: 6657), a clinical-stage biopharmaceutical company focused on cellular energy restoration therapeutics, today announced it will present clinical application experience of its investigational drug candidate...